Evolving Treatment Strategies for Triple-Negative Breast Cancer

Restricted access

Although not yet practice changing in early-stage triple-negative breast cancer, growing evidence suggests that neoadjuvant platinum-based therapy is active and that some patients may benefit from such an approach. Recent randomized phase III data suggests that carboplatin has comparable efficacy to docetaxel as first-line therapy in unselected advanced triple-negative breast cancer. In both settings, the efficacy of such treatment appears to be influenced by BRCA1/2 mutation status, with carriers of these mutations experiencing higher response rates. To optimize patient selection, biomarkers of response need to be incorporated into randomized clinical trials and validated. In addition to BRCA1/2, it is likely that measures of genomic instability and other germline biomarkers beyond BRCA1/2 may be associated with therapeutic sensitivity.

Correspondence: Melinda Telli, MD, Stanford Cancer Institute, Stanford University School of Medicine, 875 Blake Wilbur Drive, MC 5826, Room 2241, Stanford, CA 94305-5826. E-mail: mtelli@stanford.edu
  • 1.

    Von MinckwitzGSchneeweissALoiblS. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomized phase 2 trial. Lancet Oncol2014;15:747756.

    • Search Google Scholar
    • Export Citation
  • 2.

    SikovWMBerryDAPerouCM. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathology complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Aliance). J Clin Oncol2015;33:1321.

    • Search Google Scholar
    • Export Citation
  • 3.

    Von MinckwitzGHahnenEFaschingPA. Pathological complete response rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA mutation and triple-negative breast cancer: results from GeparSixto [abstract]. J Clin Oncol2014;32(Suppl):Abstract 1005.

    • Search Google Scholar
    • Export Citation
  • 4.

    TelliMLJensenKCKurianAW. PrECOG 0105: final efficacy results from a phase II study of gemcitabine and carboplatin plus iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer [abstract]. J Clin Oncol2013;31(Suppl):Abstract 1003.

    • Search Google Scholar
    • Export Citation
  • 5.

    TuttAEllisPKilburnL. The TNT trial: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative of BRCA1/2 breast cancer (CRUK/07/012) [abstract]. Presented at the 2014 San Antonio Breast Cancer Symposium; December9–132014; San Antonio, Texas. Abstract S3-01.

    • Search Google Scholar
    • Export Citation
  • 6.

    NandaRChowLQDeesEC. A phase Ib study of pembrolizumb (MK-3475) in patients with advanced triple-negative breast cancer [abstract]. Presented at the 2014 San Antonio Breast Cancer Symposium; December9–132014; San Antonio, Texas. Abstract S1-09.

    • Search Google Scholar
    • Export Citation
  • 7.

    EmensLABraitehFSCassierP. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer [abstract]. Presented at the 2014 San Antonio Breast Cancer Symposium; December9–132014; San Antonio, Texas. Abstract PD1-6.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 83 83 3
PDF Downloads 18 18 2
EPUB Downloads 0 0 0